» Articles » PMID: 23462719

Biology of Primary Breast Cancer in Older Women Treated by Surgery: with Correlation with Long-term Clinical Outcome and Comparison with Their Younger Counterparts

Overview
Journal Br J Cancer
Specialty Oncology
Date 2013 Mar 7
PMID 23462719
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: As age advances breast cancer appears to change its biological characteristics, however, very limited data are available to define the precise differences between older and younger patients.

Methods: Over 36 years (1973-2009), 1758 older (≥70 years) women with early operable primary breast cancer were managed in a dedicated clinic. In all, 813 underwent primary surgery and 575 good quality tumour samples were available for biological analysis. The pattern of biomarkers was analysed using indirect immunohistochemistry on tissue microarrays. Comparison was made with a previously characterised series of younger (<70 years) patients.

Results: There was high expression of oestrogen receptor (ER), PgR, Bcl2, Muc1, BRCA1 and 2, E-cadherin, luminal cytokeratins, HER3, HER4, MDM2 and 4 and low expression of human epidermal growth factor receptor (HER)-2, Ki67, p53, EGFR and CK17. Oestrogen receptor and axillary stage appeared as independent prognostic factors. Unsupervised partitional clustering showed six biological clusters in older patients, five of which were common in the younger patients, whereas the low ER luminal cluster was distinct in the older series. The luminal phenotype showed better breast cancer-specific survival, whereas basal and HER2-overexpressing tumours were associated with poor outcome.

Conclusion: Early operable primary breast cancer in older women appears as a distinct biological entity, with existence of a novel cluster. Overall older women showed less aggressive tumour biology and ER appeared as an independent prognostic factor alongside the time-dependent axillary stage. These biological characteristics may explain the differences in clinical outcome and should be considered in making therapeutic decisions.

Citing Articles

Updates and Future Directions for the Nottingham Research Programme on Primary Breast Cancer in Older Women.

Parks R, Cheung K Cancers (Basel). 2025; 17(3).

PMID: 39941718 PMC: 11816291. DOI: 10.3390/cancers17030346.


Chemotherapy in older patients with early breast cancer.

Schmidt M, Loibl S Breast. 2024; 78():103821.

PMID: 39405593 PMC: 11752109. DOI: 10.1016/j.breast.2024.103821.


Adjuvant chemotherapy and survival outcomes in older women with HR+/HER2- breast cancer: a propensity score-matched retrospective cohort study using the SEER database.

Ma X, Wu S, Zhang X, Chen N, Yang C, Yang C BMJ Open. 2024; 14(3):e078782.

PMID: 38490656 PMC: 10946384. DOI: 10.1136/bmjopen-2023-078782.


Assessment of the Androgen Receptor in Older Women with Primary Breast Cancer: Association with a Panel of Biomarkers and Breast Cancer Specific Survival.

Kalvala J, Parks R, Abdi J, Green A, Cheung K Adv Ther. 2023; 40(6):2820-2835.

PMID: 37118159 DOI: 10.1007/s12325-023-02504-2.


The addition of radiotherapy to breast-conserving surgery improves survival for elderly patients with early breast cancer.

Yang S, Tan L, Zhou P, Lian C, Wu S, He Z Front Oncol. 2022; 12:917054.

PMID: 36505844 PMC: 9727219. DOI: 10.3389/fonc.2022.917054.


References
1.
Rakha E, Boyce R, Abd El-Rehim D, Kurien T, Green A, Paish E . Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005; 18(10):1295-304. DOI: 10.1038/modpathol.3800445. View

2.
Sotiriou C, Neo S, McShane L, Korn E, Long P, Jazaeri A . Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003; 100(18):10393-8. PMC: 193572. DOI: 10.1073/pnas.1732912100. View

3.
Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao T, Panageas K . Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res. 2000; 6(5):1693-701. View

4.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

5.
McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005; 23(36):9067-72. DOI: 10.1200/JCO.2004.01.0454. View